Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Florbetaben
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : Florbetaben
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : Florbetaben
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : pharmtrace
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetaben
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 18, 2020
Lead Product(s) : Florbetaben
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetaben
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Bayer AG | National Institute on Aging
Deal Size : Inapplicable
Deal Type : Inapplicable
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2010
Lead Product(s) : Florbetaben
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Bayer AG | National Institute on Aging
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Florbetaben
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2010
Lead Product(s) : Florbetaben
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable